Ben Derman, Assistant Professor at University of Chicago, shared a post on X:
“Updated follow-up from the OG ReDirecTT-1: Tec+tal combination therapy
- mPFS 38.6 months overall, and 3-year PFS in the RP2R was 70% in patients without EMD.
- But…..19% AE-related deaths (mostly infections).
I want to like this regimen but the toxicity is of great concern. Still need to process why to do this regimen over CAR T – rapidly progressive disease might be a great population for this.
No doubt that this combo is potent!”
More posts featuring Ben Derman.
